InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (5 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
5
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Browse the detailed record of transactions filed by Thompson Elizabeth H.Z., Directeur de la Recherche et Développement. Director active across 2 companies, notably Horizon Therapeutics Public Ltd Co. Cumulatively, 17 reports have been published. Breakdown: 0 buy · 5 sells. Total volume traded: €2.2m. Activity tracked since 5 August 2021. The latest transaction was filed on 31 March 2025 (Attribution). Regulator: SEC (Form 4). The full history is free.
Declarations17 total
694 shares0Common StockSEC:0001415889-25-009778:0
1,452 shares0Common StockSEC:0001415889-25-000609:0
1,452 shares0Common StockSEC:0001415889-24-024534:0
1,452 shares0Common StockSEC:0001415889-24-019057:0
1,452 shares0Common StockSEC:0001415889-24-009851:0
●
14,575 shares@ US$116.5041.9% of flowOrdinary SharesSEC:0001209191-23-052363:0
2,000 shares0Common StockSEC:0001209191-23-018502:0
19,055 sharesOrdinary SharesSEC:0001209191-23-000896:0
▼
8 shares@ US$85.0150.0% of flowOrdinary SharesSEC:0001209191-22-042767:0
▼
82 shares@ US$85.010.2% of flowOrdinary SharesSEC:0001209191-22-041840:0
▼
8,098 shares@ US$115.6439.1% of flowOrdinary SharesSEC:0001209191-22-024924:0
◇
13,999 sharesOrdinary SharesSEC:0001209191-22-002295
13,999 sharesOrdinary SharesSEC:0001209191-22-002295:0
▼
7,542 shares@ US$106.341130.5% of flowOrdinary SharesSEC:0001209191-21-050212:0
▼
7,542 shares@ US$106.341117.6% of flowOrdinary SharesSEC:0001209191-21-050212
12,077 sharesOrdinary SharesSEC:0001209191-21-045062:0
◇
12,077 sharesOrdinary SharesSEC:0001209191-21-045062
17 of 17 declarations
About Thompson Elizabeth H.Z.
Elizabeth H.Z. Thompson is the Executive Vice President of Research & Development at Horizon Therapeutics Public Ltd Co. She oversees the company's research and development initiatives. Her expertise is essential in ensuring innovation and safety in the treatments offered.
